Dole (DOLE)
(Delayed Data from NYSE)
$16.15 USD
+0.08 (0.50%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $16.14 -0.01 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.15 USD
+0.08 (0.50%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $16.14 -0.01 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum B VGM
Zacks News
Dole (DOLE) Moves 7.8% Higher: Will This Strength Last?
by Zacks Equity Research
Dole (DOLE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Dole (DOLE) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Dole (DOLE) delivered earnings and revenue surprises of 55.56% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Metabolix, Inc. (YTEN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Metabolix, Inc. (YTEN) delivered earnings and revenue surprises of -1.43% and 26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dole Q2 Preview: Can Shares Find New Life?
by Derek Lewis
Over the market's rally over the last month, Dole shares have lagged notably, decreasing by 4% in value.
Do Options Traders Know Something About Dole (DOLE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Dole (DOLE) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Dole (DOLE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Dole (DOLE) stock based on the movements in the options market lately.
DOLE vs. CTVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DOLE vs. CTVA: Which Stock Is the Better Value Option?
Alico (ALCO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Alico (ALCO) delivered earnings and revenue surprises of 500% and 3.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corteva, Inc. (CTVA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Corteva, Inc. (CTVA) delivered earnings and revenue surprises of 19.75% and 1.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company News for Mar 16, 2022
by Zacks Equity Research
Companies In The News Are: GTLB, DLO, JBI, DOLE.
DOLE vs. CTVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DOLE vs. CTVA: Which Stock Is the Better Value Option?
Wall Street Analysts See a 30% Upside in Dole (DOLE): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Dole (DOLE) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
5 Lucrative PEG Stocks for GARP Investors
by Urmimala Biswas
Here are five GARP stocks, PVH, DOLE, ASO, BERY and CAR, which qualify the screening criteria.
DOLE vs. CTVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
DOLE vs. CTVA: Which Stock Is the Better Value Option?